420 Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) Acquired by Consolidated Portfolio Review Corp

Consolidated Portfolio Review Corp purchased a new stake in Intuitive Surgical, Inc. (NASDAQ:ISRG) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 420 shares of the medical equipment provider’s stock, valued at approximately $208,000.

Other institutional investors and hedge funds also recently modified their holdings of the company. Norges Bank purchased a new stake in Intuitive Surgical in the 4th quarter worth about $2,401,493,000. GAMMA Investing LLC lifted its position in shares of Intuitive Surgical by 54,010.7% in the first quarter. GAMMA Investing LLC now owns 3,028,576 shares of the medical equipment provider’s stock worth $14,999,630,000 after purchasing an additional 3,022,979 shares in the last quarter. Proficio Capital Partners LLC lifted its position in shares of Intuitive Surgical by 89,098.8% in the fourth quarter. Proficio Capital Partners LLC now owns 949,967 shares of the medical equipment provider’s stock worth $495,845,000 after purchasing an additional 948,902 shares in the last quarter. Capital Research Global Investors grew its position in Intuitive Surgical by 25.5% during the fourth quarter. Capital Research Global Investors now owns 3,381,302 shares of the medical equipment provider’s stock valued at $1,764,904,000 after purchasing an additional 687,906 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in Intuitive Surgical in the 4th quarter valued at approximately $313,769,000. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Buying and Selling at Intuitive Surgical

In related news, Director Jami K. Nachtsheim sold 2,400 shares of the business’s stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total value of $1,248,000.00. Following the sale, the director now owns 6,371 shares of the company’s stock, valued at $3,312,920. The trade was a 27.36% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Mark Brosius sold 215 shares of the company’s stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $549.06, for a total value of $118,047.90. Following the completion of the sale, the senior vice president now owns 1,768 shares in the company, valued at $970,738.08. This trade represents a 10.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,998 shares of company stock valued at $2,611,577. 0.70% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of research reports. Citigroup reissued a “buy” rating and set a $650.00 price objective (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Barclays lowered their price target on Intuitive Surgical from $684.00 to $635.00 and set an “overweight” rating for the company in a research note on Thursday, April 24th. Deutsche Bank Aktiengesellschaft lowered shares of Intuitive Surgical from a “hold” rating to a “sell” rating and cut their price objective for the company from $515.00 to $440.00 in a research report on Monday, June 9th. Royal Bank Of Canada reduced their target price on shares of Intuitive Surgical from $630.00 to $605.00 and set an “outperform” rating for the company in a research note on Wednesday, April 23rd. Finally, Evercore ISI dropped their price target on shares of Intuitive Surgical from $510.00 to $470.00 and set an “in-line” rating on the stock in a research note on Wednesday, April 23rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $588.95.

Intuitive Surgical Stock Down 0.3%

ISRG stock opened at $521.63 on Thursday. Intuitive Surgical, Inc. has a twelve month low of $413.82 and a twelve month high of $616.00. The company has a market cap of $186.96 billion, a PE ratio of 76.49, a price-to-earnings-growth ratio of 5.55 and a beta of 1.67. The business’s 50-day simple moving average is $530.03 and its 200 day simple moving average is $536.86.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share for the quarter, beating analysts’ consensus estimates of $1.71 by $0.10. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. The business had revenue of $2.25 billion for the quarter, compared to analysts’ expectations of $2.19 billion. During the same quarter in the previous year, the firm posted $1.50 earnings per share. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.